Most Read Articles
Roshini Claire Anthony, 6 days ago

Treatment failure in osteoporosis remains a problem, even among patients who are treatment-adherent, according to a presentation at the recent meeting of the Asian Federation of Osteoporosis Societies (AFOS 2017), held in Kuala Lumpur, Malaysia. 

Elvira Manzano, 5 days ago
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
2 days ago
Breast cancer patients have notably different microbiomes in the local breast tissue and urinary tract, a recent study reveals. Particularly, species in the Methylobacterium genus are reduced in the local breast tissue while the urinary tract is enriched in gram-positive bacteria.
Pearl Toh, 13 Oct 2017
Women with higher plasma tryptophan concentrations were less likely to have poor sleep quality during pregnancy, especially among those with anxiety symptoms, according to the GUSTO* study.

CASE-J 10 confirms reduction in new-onset diabetes risk among high-risk patients on candesartan

Roshini Claire Anthony
25 Jul 2017

Candesartan reduced the risk of new-onset diabetes among Japanese patients with hypertension and high cardiovascular risk after a 10-year follow-up period, confirming the findings of the CASE-J* trial, according to a study presented at APSC 2017.

“Candesartan treatment for hypertension may have some potential benefits on new-onset diabetes compared with amlodipine. These findings corroborate the results of the CASE-J and the CASE-J extension by longer follow-up,” said Dr Liu Jinliang from Kyoto University Hospital, Kyoto, Japan, who called for further research to confirm the findings in other populations.

In the 10-year follow-up study (CASE-J 10), researchers compared data of 645 patients on candesartan with 668 patients on amlodipine from the CASE-J cohort (mean age 63 years, 48.2 and 56.1 percent female, respectively), analysing study endpoints using the CASE-J and CASE-J extension cohorts (n=4,703). Blood pressure was well-controlled in patients on either treatment.

The incidence of first cardiovascular event (a composite of cardiac, cerebrovascular, renal, and vascular events, and sudden death) was comparable between patients on candesartan and amlodipine (14.7 percent vs 14.8 percent; hazard ratio [HR], 0.94, 95 percent confidence interval [CI], 0.70–1.27; p=0.703). The risk of new-onset diabetes was significantly lower among patients on candesartan compared with amlodipine (4.7 percent vs 6.4 percent; HR, 0.71, 95 percent CI, 0.52–0.97; p=0.029).  [APSC 2017, Late Breaking Trial 5]

The results reflected those of CASE-J (n=4,728) which demonstrated no significant difference in the incidence of cardiovascular events between patients on candesartan and amlodipine after 3.2 years of follow up (HR, 1.01, 95 percent CI, 0.79–1.28; p=0.969), though there was a 36 percent relative risk reduction (p=0.03) of new-onset diabetes among patients on candesartan. [Expert Rev Cardiovasc Ther 2008;6:1195-1201]

The results of 2,232 patients who were followed up for another 3 years in the CASE-J extension trial were similar, where cardiovascular event incidence was comparable between patients on candesartan and amlodipine (HR, 0.95, 95 percent CI, 0.77–1.18; p=0.650), while new-onset diabetes risk was lower among patients on candesartan (HR, 0.71, 95 percent CI, 0.51–1.00; p=0.0495). [Hypertens Res 2011;34:1295-1301]

The most notable benefit of candesartan on new-onset diabetes and mortality in CASE-J was among patients with the highest BMI, which suggests that candesartan may be more applicable for patients with hypertension and a more metabolic phenotype, said Professor Carolyn Lam from the National Heart Centre Singapore in her commentary.  

She also did not discount a potential negative impact of some antidiabetic agents on cardiovascular outcomes, as well as the low rate of new-onset diabetes and cardiovascular events as a confounding factor. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 6 days ago

Treatment failure in osteoporosis remains a problem, even among patients who are treatment-adherent, according to a presentation at the recent meeting of the Asian Federation of Osteoporosis Societies (AFOS 2017), held in Kuala Lumpur, Malaysia. 

Elvira Manzano, 5 days ago
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
2 days ago
Breast cancer patients have notably different microbiomes in the local breast tissue and urinary tract, a recent study reveals. Particularly, species in the Methylobacterium genus are reduced in the local breast tissue while the urinary tract is enriched in gram-positive bacteria.
Pearl Toh, 13 Oct 2017
Women with higher plasma tryptophan concentrations were less likely to have poor sleep quality during pregnancy, especially among those with anxiety symptoms, according to the GUSTO* study.